Shukun Technology, a Beijing medical artificial intelligence company, raised $29.5 million in a series B financing round led by China Creation Ventures, a VC firm focusing on the China TMT. Shukun combines expert and machine intelligence to improve the diagnostic experience in hospitals. Its lead product, CoronaryDoc, is being tested in clinical trials as a first-in-class AI product to diagnose heart disease. The company said it aims to address the shortage of specialized MDs in China.
Source: China Biotoday